Montelukast Ratiopharm (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Ratiopharm, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, exercise‑induced bronchoconstriction and allergic rhinitis in patients requiring controller therapy.

GNH USA supplies Montelukast Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction.

- Asthma: improves long‑term control and reduces the frequency of asthma attacks. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramps in the stomach area. - Nausea: feeling of queasiness or urge to vomit. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Allergic reactions: rash, hives, or angioedema requiring medical attention. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Montelukast, clinicians should consider several safety measures.

- Assess asthma control: ensure patient’s baseline asthma is stable before initiation. - Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Use caution in hepatic impairment: adjust use if liver disease is present. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at room temperature: keep in the original packaging, protect from moisture.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that may reduce montelukast plasma levels. - Phenobarbital: enzyme inducer that can lower montelukast effectiveness.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine): may increase risk of neuropsychiatric side effects. - Warfarin: potential for altered anticoagulant effect; monitor INR. - Theophylline: may require dose adjustment due to metabolic interactions.